Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of Appeals for the Federal Circuit, which prompted the company to say it would launch "as quickly as possible to help expand access to affordable and effective treatment."

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as litigation continues.

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of App

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for

To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.